Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE

Aberdeen Group plc increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 29.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 750,291 shares of the biopharmaceutical company’s stock after purchasing an additional 171,146 shares during the period. Aberdeen Group plc’s holdings in Xenon Pharmaceuticals were worth $33,628,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. increased its holdings in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 717 shares during the period. Danske Bank A S purchased a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth $32,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter worth $39,000. State of Wyoming boosted its position in Xenon Pharmaceuticals by 112.8% during the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 610 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its position in Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $56.85 on Friday. The company’s fifty day moving average price is $47.99 and its 200-day moving average price is $43.78. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $63.95. The firm has a market capitalization of $4.73 billion, a P/E ratio of -13.04 and a beta of 0.74.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the prior year, the business posted ($0.84) EPS. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 270,000 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $60.33, for a total value of $16,289,100.00. Following the sale, the chief executive officer owned 6,000 shares in the company, valued at $361,980. This represents a 97.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $156,706.77. Following the transaction, the insider owned 4,893 shares of the company’s stock, valued at approximately $294,118.23. This represents a 34.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 296,707 shares of company stock worth $17,845,365. Insiders own 4.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on XENE shares. HC Wainwright boosted their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Guggenheim reiterated a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $71.88.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.